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A 55-year-old  Portuguese  man  with  no  signiﬁcant  family  history  was  treated  for  10  years  for
progressive  hypertrophic  restrictive  cardiomyopathy.  A  cardiac  magnetic  resonance  imag-
ing  scan  performed  3  months  before  his  referral  showed  left  ventricular  (LV)  hypertrophy
without  inﬁltrative  cardiopathy.  The  patient  was  referred  to  our  hospital  for  cardiogenic
shock.  Echocardiography  showed  LV  hypertrophy  (Fig.  1A)  with  restrictive  pattern  of  trans-Mass  spectrometry mitral  ﬂow  (Fig.  1B),  an  LV  ejection  fraction  of  45%  and  altered  LV  global  strain  (—7.2%,
Fig.  1C).  Despite  optimized  cardiological  treatment,  the  patient  deteriorated.  To  gain  diag-
nostic  insights  and  to  help  with  a  decision  regarding  ventricular  assist  device  treatment,
a  cardiac  biopsy  was  performed,  showing  amyloid  deposition  with  strong  transthyretin
Abbreviations: LV, left ventricular; TTR, transthyretin.
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(TTR)  immunostaining  (Fig.  2A)  and  negative  kappa  and  lambda  light  chain  immunostain-
ing.  Neurological  examination  was  normal  except  for  bilateral  carpal  tunnel  syndrome.
Extensive  diagnostic  workup  —  including  repeated  immunoﬁxation  of  serum  and  urine,
serum-free  light  chain  and  total  body  computed  tomography  scan  —  remained  negative,
except  for  the  ﬁnding  of  a  heterozygous  Gly6Ser  variant  in  the  TTR  gene,  previously  known
as  a  neutral  polymorphism.  To  elucidate  the  precursor  protein  of  this  documented  cardiac
amyloidosis  (i.e.  Gly6Ser  TTR  versus  AL  protein),  a  mass  spectrometry  analysis  was  per-
formed  on  an  LV  fragment  of  the  biopsy  (Fig.  2B).  Results  conﬁrmed  that  light  chain  was
the  major  component  of  the  amyloid  deposit  (Fig.  2C).  Unfortunately,  the  patient  died
shortly  afterwards,  despite  biventricular  assist  device  implantation.
Figure 1. Echocardiographic ﬁndings. A. Apical four-chamber
view showing left ventricular hypertrophy. B. Transmitral ﬂow show-
ing a restrictive pattern. C. Left ventricular two-dimensional-strain
measurement.
Figure 2. A. Transthyretin immunostaining showing the type of
amyloidosis. B. Congo red-stained parafﬁn section under ﬂuorescent
light source: amyloid deposits with bright red colour selected for
microdissection are circled with a green line. C. LC-MS/MS-based
proteomic analysis performed on the microdissected fragments
identiﬁed immunoglobulin lambda light chain constant and variable
regions as the main components of the amyloid plaque (arrows).
The other proteins were serum proteins, such as apolipoproteins
A-IV (APOA4), A-I, (APOA1) and E (APOE) and serum amyloid P-
component (SAP), which are frequently incorporated into amyloid
plaques of all types, and stromal components such as vitronectin.
No peptides representing transthyretin were present. Results for
negative control and three different microdissections are shown.
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management  in  the  intensive  care  unit,  Dan  Judge  (Depart-
ment  of  Cardiology,  John  Hopkins,  Baltimore,  MD,  USA)  for08  
In  conclusion,  mass  spectrometry  is  an  invaluable  tool  for
etermining  amyloidosis  aetiology  in  patients  with  amyloid-
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